MAD2L2 and ovarian cancer: High expression of REV7/MAD2L2 shows higher survival probabilities in pancreatic cancer (Figure 3A), ovarian cancer (Figure 3B), and breast cancer (Figure 3C), whereas low expression of REV7/MAD2L2 exhibits an unfavorable outcome (Figure 3).